Sarepta Therapeutics (SRPT) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $0.81.
- Sarepta Therapeutics' Debt to Equity fell 1928.89% to $0.81 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.81, marking a year-over-year decrease of 1928.89%. This contributed to the annual value of $0.74 for FY2024, which is 4833.44% down from last year.
- Per Sarepta Therapeutics' latest filing, its Debt to Equity stood at $0.81 for Q3 2025, which was down 1928.89% from $0.84 recorded in Q2 2025.
- Sarepta Therapeutics' Debt to Equity's 5-year high stood at $4.01 during Q4 2022, with a 5-year trough of $0.74 in Q4 2024.
- Over the past 5 years, Sarepta Therapeutics' median Debt to Equity value was $1.44 (recorded in 2023), while the average stood at $1.66.
- As far as peak fluctuations go, Sarepta Therapeutics' Debt to Equity skyrocketed by 23940.62% in 2022, and later plummeted by 6408.87% in 2023.
- Over the past 5 years, Sarepta Therapeutics' Debt to Equity (Quarter) stood at $1.18 in 2021, then surged by 239.41% to $4.01 in 2022, then crashed by 64.09% to $1.44 in 2023, then plummeted by 48.33% to $0.74 in 2024, then increased by 9.01% to $0.81 in 2025.
- Its last three reported values are $0.81 in Q3 2025, $0.84 for Q2 2025, and $1.0 during Q1 2025.